# DBV Technologies (DBV.PA) Canonical: https://gigainvestors.com/s/DBV.PA Analysis as of: 2026-10-01T09:06:28.139Z. Listing currency: EUR. Reporting currency: USD. ## Verdict Not enough history yet Quality tests for Buy: not passed. Published buy qualification: no. Share price: EUR 1.62 per share; close as of 2026-10-15. ## Checklist ### understandable: na ### moat: na ### economics: na ### management: na ### accounting: na ## Holders ## Price story Down 67% since Oct 2021 Story as of 2026-10-03T17:10:00Z; price observation 2026-10-02. ## Owner memo Memo as of 2026-10-02T09:13:03.300Z. ### How it makes money Operates in biotechnology; annual sales are USD 5.6 million. - Source: https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm (filed 2026-03-26); FY2025: revenue 5636000; grossProfit -18338366; margin = grossProfit / revenue. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-09-29); DBV.PA: DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France. ### Where the cash goes Paid no dividends in 6 years. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-26); Dividend observations: [[2020,0],[2021,0],[2022,0],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement. ### Are managers owners Insiders own 0.1% of the company. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-09-29); DBV.PA SharesStats.PercentInsiders = 0.126 percentage points; cache date 2026-09-29. ### What could break it This program is independent from the Viaskin Peanut Program in 4-7-year-olds and uses the cVP (original patch). - Source: https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm (filed 2026-03-26); F - 8 Viaskin Peanut for Children ages 1-3 We are developing Viaskin Peanut for the treatment of peanut allergy in toddlers one to three years of age, given the high unmet need and the limited number of approved treatments for this population. This program is independent from the Viaskin Peanut Program in 4-7-year-olds and uses the cVP (original patch). The Viaskin Peanut program for toddlers comprises three Phase 3 clinical trials, with the intent for the trials to support a future BLA submission in this age group: • EPITOPE (EPIT in Toddlers with Peanut Allergy), a randomized, two-part, pivotal Phase 3 clinical trial assessing the safety and efficacy of Viaskin Peanut for the treatment of peanut-allergic toddlers one to three years of age; • COMFORT Toddlers (Characterization of the Optimal Management of Food allergy Relief and Treatment), a supplemental safety study to bring the (total) number of subjects on active therapy close to 600 in total when combined with EPITOPE; • EPOPEX (Phase 3 Open-Label Extension to the EPITOPE Trial), a follow-up of the EPITOPE study to evaluate the long-term efficacy and safety of Viaskin Peanut in very young children. ### What the price says The price is 3 times net assets; cash earnings are negative. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-26); Closing price 1.904 EUR; reporting-to-trading FX 0.8895610016456879; FY2025 net assets per share 0.7161513185609572; price multiple 2.9887281424. FY2025 cash earnings/share -0.6415396347000281. Closing-price date 2026-10-02. ## Monthly share-price history (EUR per share) - 2016-10: EUR 62.96 per share - 2016-11: EUR 68.59 per share - 2016-12: EUR 66.35 per share - 2017-01: EUR 63.08 per share - 2017-02: EUR 68.68 per share - 2017-03: EUR 65.26 per share - 2017-04: EUR 65.43 per share - 2017-05: EUR 59.40 per share - 2017-06: EUR 61.85 per share - 2017-07: EUR 75.79 per share - 2017-08: EUR 74.32 per share - 2017-09: EUR 70.42 per share - 2017-10: EUR 38.76 per share - 2017-11: EUR 37.35 per share - 2017-12: EUR 41.90 per share - 2018-01: EUR 37.76 per share - 2018-02: EUR 34.60 per share - 2018-03: EUR 38.54 per share - 2018-04: EUR 37.02 per share - 2018-05: EUR 38.72 per share - 2018-06: EUR 33.16 per share - 2018-07: EUR 30.40 per share - 2018-08: EUR 38.00 per share - 2018-09: EUR 39.16 per share - 2018-10: EUR 32.72 per share - 2018-11: EUR 26.32 per share - 2018-12: EUR 10.61 per share - 2019-01: EUR 11.43 per share - 2019-02: EUR 13.73 per share - 2019-03: EUR 13.43 per share - 2019-04: EUR 17.41 per share - 2019-05: EUR 16.79 per share - 2019-06: EUR 14.77 per share - 2019-07: EUR 17.63 per share - 2019-08: EUR 16.63 per share - 2019-09: EUR 15.70 per share - 2019-10: EUR 12.90 per share - 2019-11: EUR 13.88 per share - 2019-12: EUR 19.63 per share - 2020-01: EUR 17.53 per share - 2020-02: EUR 17.33 per share - 2020-03: EUR 7.57 per share - 2020-04: EUR 12.06 per share - 2020-05: EUR 8.39 per share - 2020-06: EUR 7.88 per share - 2020-07: EUR 6.96 per share - 2020-08: EUR 3.73 per share - 2020-09: EUR 3.09 per share - 2020-10: EUR 2.46 per share - 2020-11: EUR 4.11 per share - 2020-12: EUR 4.34 per share - 2021-01: EUR 8.57 per share - 2021-02: EUR 8.81 per share - 2021-03: EUR 8.95 per share - 2021-04: EUR 11.22 per share - 2021-05: EUR 9.38 per share - 2021-06: EUR 9.28 per share - 2021-07: EUR 9.22 per share - 2021-08: EUR 10.13 per share - 2021-09: EUR 8.66 per share - 2021-10: EUR 5.76 per share - 2021-11: EUR 5.30 per share - 2021-12: EUR 3.06 per share - 2022-01: EUR 2.74 per share - 2022-02: EUR 2.46 per share - 2022-03: EUR 2.98 per share - 2022-04: EUR 2.49 per share - 2022-05: EUR 2.95 per share - 2022-06: EUR 4.22 per share - 2022-07: EUR 4.62 per share - 2022-08: EUR 4.12 per share - 2022-09: EUR 3.57 per share - 2022-10: EUR 3.12 per share - 2022-11: EUR 2.75 per share - 2022-12: EUR 3.15 per share - 2023-01: EUR 2.63 per share - 2023-02: EUR 2.86 per share - 2023-03: EUR 3.22 per share - 2023-04: EUR 2.90 per share - 2023-05: EUR 3.36 per share - 2023-06: EUR 3.38 per share - 2023-07: EUR 2.93 per share - 2023-08: EUR 2.97 per share - 2023-09: EUR 2.66 per share - 2023-10: EUR 2.15 per share - 2023-11: EUR 1.47 per share - 2023-12: EUR 1.85 per share - 2024-01: EUR 1.74 per share - 2024-02: EUR 1.34 per share - 2024-03: EUR 1.33 per share - 2024-04: EUR 1.24 per share - 2024-05: EUR 1.14 per share - 2024-06: EUR 0.81 per share - 2024-07: EUR 0.92 per share - 2024-08: EUR 0.83 per share - 2024-09: EUR 0.73 per share - 2024-10: EUR 0.77 per share - 2024-11: EUR 0.67 per share - 2024-12: EUR 0.63 per share - 2025-01: EUR 0.80 per share - 2025-02: EUR 0.75 per share - 2025-03: EUR 1.13 per share - 2025-04: EUR 1.59 per share - 2025-05: EUR 1.50 per share - 2025-06: EUR 1.59 per share - 2025-07: EUR 1.66 per share - 2025-08: EUR 1.60 per share - 2025-09: EUR 1.68 per share - 2025-10: EUR 2.63 per share - 2025-11: EUR 2.29 per share - 2025-12: EUR 3.38 per share - 2026-01: EUR 3.81 per share - 2026-02: EUR 3.59 per share - 2026-03: EUR 3.63 per share - 2026-04: EUR 3.63 per share - 2026-05: EUR 3.36 per share - 2026-06: EUR 2.82 per share - 2026-07: EUR 2.35 per share - 2026-08: EUR 2.37 per share - 2026-09: EUR 2.02 per share ## Annual estimated value (EUR per share) Historical values use today's bond yield for every fiscal year Historical values use today's FX rate into trading currency for every fiscal year Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates ## Sources [Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm); period 2025-12-31, filed 2026-03-26. Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights. ## Reported holder observations